Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

55.6%

5 terminated/withdrawn out of 9 trials

Success Rate

44.4%

-42.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
8(88.9%)
Phase 1
1(11.1%)
9Total
Phase 2(8)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT00823095Phase 2Terminated

Topical Nitric Oxide Trial in Chronic Non-Healing Wounds

Role: collaborator

NCT00545298Phase 2Terminated

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

Role: lead

NCT00893880Phase 2Completed

A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis

Role: lead

NCT01080079Phase 2Completed

Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis

Role: lead

NCT01484145Phase 2Completed

Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

Role: lead

NCT00613808Phase 2Terminated

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

Role: lead

NCT00771368Phase 1Terminated

Reduction of Bacteria in MRSA Positive Ulcers

Role: lead

NCT00790608Phase 2Terminated

Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA)

Role: lead

NCT00771342Phase 2Completed

Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot)

Role: lead

All 9 trials loaded